10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549 

FORM 10-Q

(Mark One)

þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2013

or

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934

For the transition period from __________ to ____________

Commission File Number: 2-93277-D

MEDIZONE INTERNATIONAL, INC.

(Exact name of registrant as specified in its charter)

Nevada	87-0412648
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

4000 Bridgeway, Suite 401, Sausalito, California  94965

(Address of principal executive offices, Zip Code)

(415) 331-0303

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   Yes þ No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  Yes þ No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ¨	Accelerated filer ¨
Non-accelerated filer ¨ (Do not check if a smaller reporting company)	Smaller Reporting Company þ

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes ¨ No þ

As of October 31, 2013, the registrant had 317,612,639 shares of common stock issued and outstanding.

MEDIZONE INTERNATIONAL, INC.

FORM 10-Q

TABLE OF CONTENTS

September 30, 2013

			Page No.
Part I — Financial Information
Item 1.	Financial Statements (Unaudited)		3
		Condensed Consolidated Balance Sheets as of September 30, 2013 and December 31, 2012	3
		Condensed Consolidated Statements of Comprehensive Loss for the Three and Nine Months Ended September 30, 2013 and 2012	4
		Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2013 and 2012	5
		Notes to the Condensed Consolidated Financial Statements	7
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations		12
Item 3.	Quantitative and Qualitative Disclosures About Market Risk		15
Item 4.	Controls and Procedures		15
Part II — Other Information
Item 1.	Legal Proceedings		16
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds		16
Item 5.	Other Information		16
Item 6.	Exhibits		16
Signatures			17

PART I – FINANCIAL INFORMATION

Item 1.  Financial Statements

MEDIZONE INTERNATIONAL, INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

(Unaudited)

	September 30,				December 31,
	2013				2012 (1)
ASSETS
Current Assets:
Cash		$	140,774			$	12,456
Inventory			-				45,548
Prepaid expenses			325,674				118,344
Total Current Assets			466,448				176,348
Property and Equipment, net			8,162				5,964
Other Assets:
Trademark and patents, net			212,808				208,490
Lease deposit			4,272				4,272
Total Other Assets			217,080				212,762
Total Assets		$	691,690			$	395,074
LIABILITIES AND STOCKHOLDERS' DEFICIT
Current Liabilities:
Accounts payable		$	438,606			$	453,885
Accounts payable – related parties			234,572				234,572
Accrued expenses			504,632				487,690
Accrued expenses – related parties			1,928,659				1,975,084
Customer deposits			30,000				34,554
Notes payable			310,334				298,536
Total Current Liabilities			3,446,803				3,484,321
Other Payables			224,852				224,852
Total Liabilities			3,671,655				3,709,173
Commitments and Contingencies (Notes 4 and 5)
Stockholders’ Deficit:
Preferred stock, $0.00001 par value; 50,000,000 shares authorized, no shares issued or outstanding			-				-
Common stock, $0.001 par value, 395,000,000 shares authorized,        315,662,639 and 288,771,227 shares issued       and outstanding, respectively			315,663				288,771
Additional paid-in capital			27,771,790				26,506,566
Accumulated other comprehensive loss			(24,530	)			(24,444	)
Accumulated deficit			(31,042,888	)			(30,084,992	)
Total Stockholders' Deficit			(2,979,965	)			(3,314,099	)
Total Liabilities and Stockholders’ Deficit		$	691,690			$	395,074

(1)   The condensed consolidated balance sheet as of December 31, 2012 has been prepared using information from the audited balance sheet as of that date.   

The accompanying notes are an integral part of these condensed consolidated financial statements.

3

MEDIZONE INTERNATIONAL, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Comprehensive Loss

(Unaudited)

	For the Three Months Ended						For the Nine Months Ended
	September 30,						September 30,
	2013			2012			2013			2012
Revenues	$	-		$	150,000		$	379,554		$	150,000
Operating Expenses:
Cost of revenues		-			86,725			239,436			86,725
General and administrative		263,385			932,872			856,664			2,514,018
Research and development		64,761			187,126			184,643			546,054
Depreciation and amortization		11,420			9,561			37,827			26,488
Total Operating Expenses		339,566			1,216,284			1,318,570			3,173,285
Loss from Operations		(339,566	)		(1,066,284	)		(939,016	)		(3,023,285	)
Interest Expense		(6,125	)		(6,097	)		(18,880	)		(18,445	)
Net Loss		(345,691	)		(1,072,381	)		(957,896	)		(3,041,730	)
Other Comprehensive Loss:
Gain (loss) on foreign currency translation		1,282			957			(86	)		(1,589	)
Total Comprehensive Loss	$	(344,409	)	$	(1,071,424	)	$	(957,982	)	$	(3,043,319	)
Basic and Diluted Net Loss per Common Share	$	(0.00	)	$	(0.00	)	$	(0.00	)	$	(0.01	)
Weighted Average Number of Common Shares Outstanding		312,649,052			282,697,797			304,549,347			280,103,399

The accompanying notes are an integral part of these condensed consolidated financial statements.

4

MEDIZONE INTERNATIONAL, INC. AND SUBSIDIARIES

 Condensed Consolidated Statements of Cash Flows

(Unaudited)

	For the Nine Months Ended
	September 30,
	2013			2012
Cash Flows from Operating Activities:
Net loss	$	(957,896	)	$	(3,041,730	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		37,576			26,416
Value of stock options granted		131,866			1,931,325
Changes in operating assets and liabilities:
Prepaid expenses		(144,343	)		28,724
Inventory		45,548			(91,547	)
Customer deposits		(4,554	)		10,000
Accounts payable (includes related parties)		(15,280	)		59,931
Accrued expenses (includes related parties)		(29,483	)		26,611
Net Cash Used in Operating Activities		(936,566	)		(1,050,270	)
Cash Flows from Investing Activities:
Purchase of trademark and patents		(36,551	)		(89,118	)
Purchase of property and equipment		(7,540	)		(3,148	)
Net Cash Used in Investing Activities		(44,091	)		(92,266	)
Cash Flows from Financing Activities:
Principal payments on notes payable		(51,189	)		(26,449	)
Issuance of common stock for cash		1,160,250			1,284,935
Net Cash Provided by Financing Activities		1,109,061			1,258,486
Effect of Foreign Currency Exchange Rates		(86	)		(1,589	)
Net increase in cash		128,318			114,361
Cash as of beginning of the period		12,456			129,759
Cash as of end of the period	$	140,774		$	244,120

The accompanying notes are an integral part of these condensed consolidated financial statements.

5

MEDIZONE INTERNATIONAL, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows (Continued)

(Unaudited)

	For the Nine Months Ended
	September 30,
	2013		2012
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash Paid for Interest	$	697	$	702
NON-CASH FINANCING ACTIVITIES:
Financing of insurance policies	$	62,987	$	54,678

The accompanying notes are an integral part of these condensed consolidated financial statements.

6

MEDIZONE INTERNATIONAL, INC. AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements (Unaudited)

NOTE 1     BASIS OF PRESENTATION

The financial information included herein is unaudited and has been prepared consistent with United States generally accepted accounting principles (“US GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, these condensed consolidated financial statements do not include all information and notes required by US GAAP for complete financial statements. These notes should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2012. In the opinion of management, these financial statements contain all adjustments (consisting solely of normal recurring adjustments) which are, in the opinion of management, necessary to provide a fair presentation for the interim periods. The results of operations for the three and nine months ended September 30, 2013 are not necessarily indicative of the results to be expected for the full year.

NOTE 2     CANADIAN FOUNDATION FOR GLOBAL HEALTH

In late 2008, the Company assisted in the formation of the Canadian Foundation for Global Health (“CFGH”), a not-for-profit foundation based in Ottawa, Canada. The Company helped establish CFGH for two primary purposes: (1) to establish an independent not-for-profit foundation intended to have a continuing working relationship with the Company for research purposes that is best positioned to attract the finest scientific, medical and academic professionals possible to work on projects deemed to be of social benefit; and (2) to provide a means for the Company to use a tiered pricing structure for services and products in emerging economies and extend the reach of the Company’s technology to as many in need as possible.

US GAAP requires a variable interest entity (“VIE”) to be consolidated by a company if that company absorbs a majority of the VIE’s expected losses and/or receives a majority of the entity’s expected residual returns as a result of holding variable interests, which are the ownership, contractual, or other financial interests in the entity. In addition, a legal entity may be considered to be a VIE, if it does not have sufficient equity at risk to finance its own activities without relying on financial support from other parties. If the legal entity is a VIE, then the reporting entity determined to be the primary beneficiary of the VIE must consolidate the VIE’s financial statements with its own. The Company determined that CFGH meets the requirements of a VIE effective upon the first advance to CFGH on February 12, 2009. Accordingly, the financial position and operations of CFGH have been consolidated with the Company for all periods presented.

NOTE 3     BASIC AND DILUTED NET LOSS PER COMMON SHARE

The computations of basic and diluted net loss per common share are based on the weighted average number of common shares outstanding during the periods as follows:

	For the Three Months Ended September 30,
	2013			2012
Numerator: Net loss	$	(345,691	)	$	(1,072,381	)
Denominator: Weighted average number of common shares outstanding		312,649,052			282,697,797
Basic and diluted net loss per common share	$	(0.00	)	$	(0.00	)

	For the Nine Months Ended September 30,
	2013			2012
Numerator: Net loss	$	(957,896	)	$	(3,041,730	)
Denominator: Weighted average number of common shares outstanding		304,549,347			280,103,399
Basic and diluted net loss per common share	$	(0.00	)	$	(0.01	)

Common stock equivalents, consisting of options to purchase a total of 15,150,00 shares of common stock, have not been included in the calculation as their effect is antidilutive for the periods presented.

7

MEDIZONE INTERNATIONAL, INC. AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements (Unaudited)

NOTE 4     GOING CONCERN

The Company’s consolidated financial statements are prepared using US GAAP applicable to a going concern which contemplates the realization of assets and settlement of liabilities in the normal course of business.  The Company has incurred significant losses from its inception through September 30, 2013, which have resulted in an accumulated deficit of $31,042,888 as of September 30, 2013.  The Company does not have funds sufficient to cover its operating costs for the next 12 months, has a working capital deficit of $2,980,355, and has relied on debt and equity financing to sustain its operations.  Accordingly, there is substantial doubt about its ability to continue as a going concern.

Continuation of the Company as a going concern is dependent upon future revenues, obtaining additional capital and ultimately, upon the Company’s attaining profitable operations.  The Company will require substantial, additional funds to complete the development of its products, perform hospital beta testing and fund additional losses, until future revenues are sufficient to cover the Company’s operating expenses. If the Company is unsuccessful in obtaining additional funding, it may be forced to substantially reduce or cease operations.

The Company believes that it will need approximately $2,000,000 over the next 12 months for continuing research expenses, marketing, and related activities, as well as for general corporate purposes, including expanded manufacturing and sales.  

During 2012, the Company raised a total of $1,420,793 through the sale of 16,729,278 shares of common stock at prices ranging from $0.05 to $0.165 per share, which funds have been used pay current obligations and to pay for the initial costs of development for its hospital disinfection system.  During the nine months ended September 30, 2013, the Company raised a total of $1,160,250 through the sale of 26,891,412 shares of common stock at prices ranging from $0.03 to $0.06 per share.  The Company believes it will be able to raise additional funds from some of the same investors who have purchased shares from 2009 to 2013, although there is no guarantee that these investors will purchase additional shares.  Certain of these investors have orally committed to continue to fund the Company’s projects on a monthly basis.

Continuing as a going concern is dependent on the Company’s ability to successfully accomplish the plan described in the preceding paragraphs and eventually attain profitable operations.  The consolidated financial statements do not include any adjustments relating to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities that might result from the outcome of these uncertainties.

NOTE 5     COMMITMENTS AND CONTINGENCIES

The Company is subject to certain claims and lawsuits arising in the normal course of business. In the opinion of management, uninsured losses, if any, resulting from the ultimate resolution of these matters will not have a material effect on the Company’s consolidated financial position or results of operations.

Litigation

Rakas vs. Medizone International, Inc. - A former consultant brought this action against the Company claiming the Company had failed to pay consulting fees under a consulting agreement.  In September 2001, the parties agreed to settle the matter for $25,000.  The Company, however, did not have the funds to pay the settlement and the plaintiff moved the court to enter a default judgment in the amount of $143,000 in January 2002.  On May 8, 2002, the court vacated the default judgment and requested that the Company post a bond of $25,000 to cover the settlement previously entered into by the parties.  The Company has been unable to post the required bond amount as of the date of this report.  Therefore, the Company has recorded a liability (included in accounts payable) for the original default judgment of $143,000, plus fees totaling $21,308, as of September 30, 2013 and December 31, 2012.  The Company intends to contest the judgment when it is able to do so in the future.

Other Payables

As of September 30, 2013 and December 31, 2012, the Company has recorded other payables totaling $224,852 for past due amounts owing for which the Company has not received invoices or demands for over 10 years.  Although management of the Company does not believe that the amounts will be paid, the amounts are being recorded as other payables until such time as the Company is certain that no liability exists and until the statute of limitations has expired.

8

MEDIZONE INTERNATIONAL, INC. AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements (Unaudited)

NOTE 5     COMMITMENTS AND CONTINGENCIES (continued)

Operating Leases

The Company operates a certified laboratory located at Innovation Park, Queen’s University in Kingston, Ontario, Canada, which provides a primary research and development platform.  The lease term expired on June 30, 2012, and is now month-to-month with a monthly lease payment of $1,375 Canadian dollars (“CD”) plus the applicable goods and services tax (“GST”). A lease for a second laboratory space for full scale room testing and a storage space also expired on June 30, 2012, and is now month-to-month with a monthly lease payment of $1,375 CD and $475 CD, respectively, plus the applicable GST.  

The Company entered into a corporate office lease effective from January 1, 2012 through December 31, 2012 with monthly payments of $2,100.  The lease term was extended for another year, through December 31, 2013, with monthly lease payments increasing from $2,100 to $2,200.  

NOTE 6     COMMON STOCK OPTIONS

On August 26, 2009, the Company granted options for the purchase of 1,500,000 shares of common stock to an outside consultant for services rendered, with an exercise price of $0.10 per share, exercisable for up to five years, but including vesting provisions as follows: (i) options for 500,000 shares vested immediately on the date of grant, (ii) options for 500,000 shares vested in September 2012, the date certified by the Company as the date its hospital disinfection program completed its beta-testing, and (iii) the remaining options for 500,000 shares will vest on the date certified by the Company as the date that its disinfection process has been commercialized and a minimum of 50 units or devices have been sold to third parties.  During the three months ended September 30, 2012, options for 500,000 shares valued at $48,699 vested, and were recorded as part of general and administrative expenses. As of September 30, 2013, options for 500,000 shares had not yet vested.

In July 2010, the Company granted options for the purchase of 3,500,000 shares of common stock (of which 250,000 were cancelled in 2011) to certain board members and employees of the Company for services rendered.  These options are exercisable for five years from the date of grant at $0.20 per share, and the remaining options vested when the Company achieved commercial sales during the third quarter of 2012, resulting in $659,822 being recorded as part of general and administrative expense. 

In September 2010, the Company granted options for the purchase of 250,000 shares of common stock to a consultant in connection with extending his consulting agreement with the Company through September 2011.  These options are exercisable at $0.275 per share for five years from the date of grant and vested when the Company achieved commercial sales during the third quarter of 2012, resulting in $65,067 being recorded as part of general and administrative expense.  

In February 2012, the Board of Directors approved the 2012 Equity Incentive Award Plan and authorized up to 10,000,000 shares of common stock to be available for awards under the Plan.  On February 21, 2012, each of four directors of the Company was awarded stock options for the purchase of 1,000,000 shares of common stock, exercisable at a price of $0.23 per share, which was the fair value of the common stock based on the price of the Company’s common stock reported on the OTC Bulletin Board on the date of grant.  In addition, certain officers, consultants and employees of the Company were awarded options for the purchase of an aggregate 1,050,000 shares of common stock at an exercise price of $0.23 per share.  The value of these options granted, totaling $1,057,600, was recognized as expense during the nine months ended September 30, 2012 as each of the options granted was fully vested on the date of grant.

In May 2012, the Company granted options for the purchase of 1,000,000 shares of common stock to an individual for services.  Options for 550,000 shares have vested and the remaining options will vest on the date certified by the Company as the date that the other milestones are achieved.  The options have an exercise price of $0.15 per share, and are exercisable for up to five years.  The value of these options granted was $153,997 in connection with which the Company recognized $69,300 during the nine months ended September 30, 2013.  As of September 30, 2013, options for the purchase of 550,000 shares have vested.

In May 2012, the Company granted options for the purchase of 1,000,000 shares of common stock to an individual for medical consulting support services already performed and to be performed in the future.  The options have an exercise price of $0.17 per share, and are exercisable for up to five years.  The value of the options vested upon grant was $149,460, of which the Company recognized $49,322 and $100,138 during the nine months ended September 30, 2013 and 2012, respectively.  As of September 30, 2013, all of the milestones were achieved and all of the shares vested.

In August 2012, the Company granted options for the purchase of 2,500,000 shares of common stock to three individuals in connection with the purchase of restricted stock, exercisable at a price of $0.05 per share.  No expense was recorded for these options as the value associated with these options was recorded as part of the stock transactions.  These options held a six-month term and have expired without being exercised. 

9

MEDIZONE INTERNATIONAL, INC. AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements (Unaudited)

NOTE 6     COMMON STOCK OPTIONS (continued)

In August 2013, the Company granted options for the purchase of 250,000 shares of common stock to a consultant.  These options are exercisable at $0.10 per share for five years from the date of grant with 50,000 shares vesting immediately and the other 200,000 upon the achievement of certain milestones.  The value of these options granted was $22,075 of which the Company recognized $4,415 which was recorded as part of general and administrative expense during the three months ended September 30, 2013.  

In August 2013, the Company granted options for the purchase of 100,000 shares of common stock to an employee for services already performed.  The options have an exercise price of $0.10 per share, and are exercisable for up to five years.  The value of the options vested upon grant was $8,830 which the Company recorded as part of general and administrative expense during the three months ended September 30, 2013.

The Company estimated the fair value of the stock options described in the above paragraphs at the date of the grant, based on the following weighted average assumptions:

Risk-free interest rate	.75	%	to	1.66	%
Expected life				5 years
Expected volatility	138.3	%	to	148.9	%
Dividend yield				0.00	%

A summary of the status of the Company’s outstanding options as of September 30, 2013, and for the nine months then ended, is presented below:

	Shares			Weighted Average Exercise Price
Outstanding, beginning of the period		17,300,000		$	0.17
Granted		350,000			0.10
Expired/Canceled		(2,500,000	)		0.05
Exercised		-			-
Outstanding, end of the period		15,150,000			0.19
Exercisable		14,000,000		$	0.19

The Company estimates the fair value of each stock award by using the Black-Scholes option-pricing model, which model requires the use of exercise behavior data and the use of a number of assumptions including volatility of the Company’s stock price, the weighted average risk-free interest rate, and the weighted average expected life of the options. Because the Company does not pay dividends, the dividend rate variable in the Black-Scholes option-pricing model is zero. Expense of $131,866 and $1,931,325 related to stock options was recorded for the nine months ended September 30, 2013 and 2012, respectively.  As of September 30, 2013, the Company had various unvested outstanding options with related unrecognized expense of $135,657.  The Company will recognize this expense as these options vest over their remaining lives, which range from 11 to 59 months.

NOTE 7     STOCK TRANSACTIONS AND SIGNIFICANT CONTRACTS

During August and September 2013, the Company sold 5,000,000 restricted shares of common stock to eight accredited investors for cash proceeds totaling $300,000, or $0.06 per share.

During May and June 2013, the Company sold 5,863,636 restricted shares of common stock to 11 accredited investors for cash proceeds totaling $322,500, or $0.055 per share.

During April and May 2013, the Company sold 3,794,444 restricted shares of common stock to six accredited investors for cash proceeds totaling $170,750, or $0.045 per share.

During January, February, and March 2013, the Company sold an aggregate of 12,233,332 restricted shares of common stock to 12 accredited investors for cash proceeds totaling $367,000, or $0.03 per share.

During January and February 2012, the Company sold an aggregate of 6,653,000 restricted shares of common stock to 30 accredited investors for cash proceeds of $665,300, or $0.10 per share.

10

MEDIZONE INTERNATIONAL, INC. AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements (Unaudited)

NOTE 7     STOCK TRANSACTIONS AND SIGNIFICANT CONTRACTS (continued)

During July, August and September 2012, the Company sold an aggregate of 5,233,333 restricted shares of common stock to 11 accredited investors for cash proceeds of $296,500 at prices ranging from $0.05 to $0.09 per share.

Stock Purchase Agreement

In November 2010, the Company entered into a two-year Stock Purchase Agreement with Mammoth providing for the Equity Line. The Stock Purchase Agreement provided that, upon the terms and subject to the conditions in the Stock Purchase Agreement, Mammoth committed to purchase up to $10,000,000 of shares of common stock over the term of the Stock Purchase Agreement under certain specified conditions and limitations. Mammoth was barred from purchasing any shares of the Company’s common stock which, when aggregated with all other shares of common stock then beneficially owned by Mammoth, would result in the beneficial ownership by Mammoth of more than 4.9% of the then outstanding shares of the Company’s common stock. These maximum share and beneficial ownership limitations could not be waived by the parties.

Under the terms of the Stock Purchase Agreement, the Company had the opportunity for a 24-month period, commencing on the date on which the Securities and Exchange Commission (“SEC”) first declared effective the registration statement filed in connection with the resale of shares issued under the Equity Line, to require Mammoth to purchase up to $10,000,000 in shares of common stock. For each share of common stock purchased under the Stock Purchase Agreement, Mammoth would pay a purchase price equal to 75% of the lowest closing bid price during the five consecutive trading-day period (the “Draw Down Pricing Period”) preceding the date a draw down notice (the “Draw Down Notice”) was delivered by the Company to Mammoth (the “Draw Down Date”) in a manner provided by the Stock Purchase Agreement.  The SEC declared the registration statement effective on January 25, 2011.  The Stock Purchase Agreement and Equity Line terminated on January 25, 2013.

Wood Wyant Canada

In April 2013, the Company and Wood Wyant Canada (“Wood Wyant”), a subsidiary of Sanimarc Group, announced that Wood Wyant had become a National Hospital Distributor of AsepticSure® in Canada.  Wood Wyant serves Canada from 16 locations across all 10 provinces, providing both sales and service to the hospital market.  The Company delivered an initial order for five systems to Wood Wyant for proceeds totaling $375,000.  The Company has six more systems in production.

ADA Innovations

In December 2010, the Company reached a Services Agreement with ADA Innovations (“ADA”) for final development and production manufacturing of portable versions (the “Projects”) of the Company’s AsepticSure® disinfection systems.  A contract containing the terms of the agreement and detailed development plan was executed by the parties in January 2011 and amended in January 2012.  Any and all notes, reports, information, inventions, sketches, plans, concepts, data or other works created by ADA on its behalf under the Services Agreement will be the sole and exclusive property of the Company.

The term of the Services Agreement continues until the completion of the development and design projects contemplated by the Services Agreement, unless terminated earlier by either party in accordance with specific notices as outlined in the Services Agreement.  Deliverables include: (1) the pre-production prototype designed and manufactured to the Company’s specifications, (2) design and device content compliant with all North America, Europe and United Kingdom regulatory and licensing agency regulations, (3) a soft launch program managed by ADA and the Company, intended to be followed by increased production, and (4) additional outsourced macro-manufacturing capacity as required, supervised by the parties.  The Company paid ADA as services were provided and were completed by December 31, 2012.  During the three and nine months ended September 30, 2012, the Company incurred expenses totaling approximately $49,000 and $157,000, respectively, for services provided under the Services Agreement, which expenses have been included in research and development expense.  No expenses under this contract were incurred during the three and nine months ended September 30, 2013.  ADA’s role as developer of the production AsepticSure® system is now complete.  ADA remains available to the Company on a limited basis as a consultant.

NOTE 8     ACCOUNTS PAYABLE – RELATED PARTIES

As of September 30, 2013 and December 31, 2012, the Company had payables of $234,572, owed to certain consultants for services rendered in prior years. These consultants are stockholders of the Company and therefore have been classified as related parties.

NOTE 9     SUBSEQUENT EVENTS

The Company has evaluated events subsequent to September 30, 2013 for potential accounting or disclosure in the accompanying financial statements, noting the following.  During October 2013, the Company sold 1,950,000 restricted shares of common stock to 5 accredited investors for cash proceeds totaling $97,500, or $0.05 per share.

11

Item 2.  Management's Discussion and Analysis of Financial Condition and Results of Operations

Introduction

Medizone International, Inc. and subsidiaries (collectively, “Medizone,” the “Company,” “we,” “us,” or “our”) had been in the development stage conducting research into the use of ozone in the disinfection of surgical and other medical treatment facilities and in other applications through the second quarter of 2012.  During the third quarter of 2012, we emerged from the development stage as we began to sell our patented ozone disinfection system, AsepticSure®.

Recent Developments

We took delivery at the end of January 2013 of the first AsepticSure® system constructed by our new contract manufacturer, Transformix Engineering, located in Kingston, Ontario, Canada (“Transformix”).  Transformix delivered an additional four units from the initial build order during February 2013.  The units passed performance confirmation testing at our Innovation Park laboratories.  The build quality of the system appears to be very good.  We believe we now have a manufacturing source that is capable of meeting our anticipated production requirements.  Six additional systems are in the late stage of production and are scheduled for delivery in the fourth quarter of 2013.

In January 2013, Singapore issued us our Health Care Patent (P-no.: 176977 ‒ Healthcare Facility Disinfecting Process and System with Oxygen/Ozone Mixture).  We consider this significant for our business growth in Asia.  According to published reports, the treatment of non-resident and foreign patients (the “medical tourism market”) in Singapore has been growing rapidly and as reported by the Singapore press holdings on-line portal AsiaOne, there were approximately 850,000 foreign patients treated in Singapore medical facilities during 2012, producing revenues of about $3.5 billion.  We believe Singapore could become a lucrative market for AsepticSure® sales as the medical system there seeks to distinguish itself with the safest hospitals possible in order to promote continued growth in the expanding medical tourism market.

In January 2013, we completed successful safety and preliminary operational trials of the AsepticSure® system at the Belleville General Hospital site of Quinte Health Care in Canada.  Belleville General is a medium-sized community hospital affiliated with Queen’s University in Ontario, Canada.  In collaboration with Contamination Control Company (C3), an Ontario-based provider of AsepticSure® services in Canada, these trials are believed to unequivocally demonstrate the safety and ease of operation of the AsepticSure® disinfection system in a functioning health care setting.  During the tests, the turnaround time for disinfection and reoccupation of the hospital rooms was less than 90 minutes.

In April 2013, we entered into an agreement with Wood Wyant Canada (“Wood Wyant”), a subsidiary of Sanimarc Group, to become a National Hospital Distributor of AsepticSure® in Canada.  Wood Wyant is national in scope and regional in focus, serving Canada from 16 diverse locations across all 10 provinces, providing both sales and service to the hospital market.  We delivered an initial order of five systems to Wood Wyant for proceeds totaling $375,000.

In July 2013, Belleville General Hospital suffered an outbreak of MRSA (Methicillin-Resistant Staphylococcus Aureus) infections.  The hospital requested the help of Medizone in quelling the outbreak.  All of the rooms that had been quarantined due to the outbreak have now been disinfected with AsepticSure® and returned to service.  This disinfection process demonstrated the high level of safety of our AsepticSure® process in an operational hospital setting.  Comparing sampling results before and after the contaminated ward-rooms were treated, it appears to confirm 100% bactericidal kill was achieved (>6-log) for the pathogens involved. To date, we have not been made aware of any new re-infection issues in any of the rooms disinfected with AsepticSure in July.

               On October 8,2013, the United States Patent and Trademark Office issued the Company US Patent Number 8,551,399 titled “Healthcare Facility Disinfecting System.”  Our Health Care patent application has now been granted in the United States, Canada and Singapore.  The application is also pending in the 38 member countries that are parties to the European Union (“EU”) Patent Treaty, as well as Korea, Japan, China, India, Brazil and Mexico.  We expect that this ruling by the US Examiner will prove favorable for us in connection with other pending applications. As an example, the application for our government variant of AsepticSure (designed for building remediation following biological attack), was originally challenged by the US Examiner, stating many of the same objections as originally stated for our Health Care application. Now that we've received a grant of the health care patent, we anticipate that the successful approach to overcoming those same objections for the government variant is likely to be accepted.

Results of Operations

Three Months Ended September 30, 2013 and 2012

During the third quarter of 2012, we exited the development stage as we commenced planned principal operations and had revenues of $150,000 with cost of revenues of $86,725.  During the quarter ended September 30, 2013, we had no revenues or cost of revenues. All of our revenues have been from the sale of AsepticSure® devices.

12

For the three months ended September 30, 2013, we had a net loss of $345,691, compared with a net loss for the three months ended September 30, 2012 of $1,072,381.  The reduction in net loss for the quarter ended September 30, 2013 compared to the same quarter of 2012, was due to lower research and development, general and administration expenses as well as significantly lower additional expense recorded as a result of options granted to directors, employees and consultants in 2012.  Our primary expenses are cost of manufacturing, payroll and consulting fees, research and development costs, office expenses and interest expense.

 For the three months ended September 30, 2013 and 2012, we incurred $263,385 and $932,872, respectively, in general and administrative expenses. The majority of these expenses include payroll, consulting fees and professional fees.  The decrease during the three months ended September 30, 2013 over the prior year comparable period was primarily the result of the expense associated with options granted to directors, employees and consultants in 2012.  The remaining general and administrative expenses include rent, office and travel expenses.

For the three months ended September 30, 2013 and 2012, we incurred $64,761 and $187,126, respectively, in research and development expenses.  Research and development expenses include consultant fees, interface development costs, prototypes, and research stage ozone generator and instrument development and significantly decreased from the prior year period as we have now commenced planned operations.

Principal amounts owed on notes payable totaled $310,334 and $298,536 as of September 30, 2013 and December 31, 2012, respectively.  Interest expense on these obligations during the three months ended September 30, 2013 and 2012 was $6,125 and $6,097, respectively. The applicable interest rates on this debt ranged from 7.75% to 10.00% per annum.

Nine Months Ended September 30, 2013 and 2012

For the nine months ended September 30, 2013, we had a net loss of $957,896, compared with a net loss for the nine months ended September 30, 2012 of $3,041,730. Our primary expenses are payroll, consulting fees, research and development costs, office expenses, interest expense and any additional expense recorded as a result of options granted to directors, employees and consultants.  The reduction in net loss for the nine months ended September 30, 2013 compared to the same period in 2012, was due to an increase in revenues, lower operating expenses and significantly less expense from options granted to directors, employees and consultants in 2012.

For the nine months ended September 30, 2013 and 2012, we incurred $856,664 and $2,514,018, respectively, in general and administrative expenses. The primary decrease for the nine months ended September 30, 2013 compared to the same period in 2012, was the grant in 2012 of options to directors, officers and employees resulting in compensation expense of approximately $1,700,000.  Our primary expenses are payroll, consulting fees, and professional fees. The remaining general and administrative expenses include rent, office expenses and travel expenses.

For the nine months ended September 30, 2013 and 2012, we incurred $184,643 and $546,054, respectively, in research and development costs as a result of prototype development costs, consulting, and other research activities. The primary decrease for the nine months ended September 30, 2013 compared to the same period in 2012, was less research and development and prototype development costs as the Company commenced planned operations.  Research and development expenses include consultant fees, interface development costs, prototypes, and research stage ozone generator and instrument development.

Interest expense on the notes payable during the nine months ended September 30, 2013 and 2012 was $18,880 and $18,445, respectively. The applicable interest rates on this debt ranged from 7.75% to 10.00% per annum.

Liquidity and Capital Resources

As of September 30, 2013, our working capital deficit was $2,980,355, compared to a working capital deficit of $3,307,973 as of December 31, 2012. We have incurred significant losses from inception through September 30, 2013, which have resulted in an accumulated deficit of $31,042,888.  The stockholders’ deficit as of September 30, 2013 was $2,979,965, compared to $3,314,099 as of December 31, 2012.

In the third quarter of 2012, we emerged from the development stage.  We will continue to require additional financing to fund operations and to undertake our new business plans, to further ongoing testing, and to market our hospital and medical disinfection system.  We believe that we will need approximately $2,000,000 over the next 12 months for continuing research expenses, marketing, product manufacturing and related activities, as well as for general corporate purposes.

13

During the nine months ended September 30, 2013, we generated cash of $1,160,250 through the sale of 26,891,412 shares of common stock to 26 accredited investors at prices ranging from $0.03 to $0.06 per share.  We anticipate that we will be able to raise additional funds, as needed, from certain of the accredited investors who have purchased shares during previous years, although we have no agreements at this time with any of these investors, and there is no assurance that these investors will purchase additional shares.

Going Concern

Our unaudited condensed consolidated financial statements included in this report have been prepared on the assumption that the Company will continue as a going concern. There is substantial doubt that the Company will be able to continue as a going concern.  Through the date of this report, it has been necessary to rely upon financing from the sale of our equity securities to sustain operations as indicated above. Additional financing will be required if we are to continue as a going concern. If additional financing is not obtained in the near future, we will be required to curtail or discontinue operations, or seek protection under the bankruptcy laws. Even if additional financing becomes available, there can be no assurance that it will be on terms favorable to the Company. In any event, this additional financing will likely result in immediate and possibly substantial dilution to existing stockholders.

Forward-Looking Statements and Risks Affecting the Company

The statements contained in this report on Form 10-Q that are not historical are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements discuss our expectations, hopes, beliefs, anticipations, commitments, intentions and strategies regarding the future. They may be identified by the use of the words or phrases “believes,” “expects,” “anticipates,” “should,” “plans,” “estimates,” and “potential,” among others. Forward-looking statements include, but are not limited to, statements contained in Management's Discussion and Analysis of Financial Condition and Results of Operations regarding our financial performance, revenue and expense levels in the future and the sufficiency of existing assets to fund future operations and capital spending needs. Actual results could differ materially from the anticipated results or other expectations expressed in such forward-looking statements for the reasons detailed in our Annual Report on Form 10-K for the year ended December 31, 2012.

We believe that many of the risks previously discussed in our SEC filings are part of doing business in the industry in which we operate and will likely be present in all periods reported. The fact that certain risks are endemic to the industry does not lessen their significance. The forward-looking statements contained in this report are made as of the date of this report and we assume no obligation to update them or to update the reasons why actual results could differ from those projected in such forward-looking statements. Among others, risks and uncertainties that may affect our business, financial condition, performance, development, and results of operations include:

• Rigorous government scrutiny and regulation of our products and planned products;

• Potential effects of adverse publicity regarding ozone and related technologies or industries;

• Failure to sustain or manage growth including the failure to continue to develop new products; and

• The ability to obtain needed financing.

Critical Accounting Policies and Estimates

Management’s Discussion and Analysis of Financial Condition and Results of Operations is based upon our unaudited condensed consolidated financial statements, which have been prepared in accordance with United States generally accepted accounting principles (“US GAAP”). The preparation of such statements requires our management to make significant estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. By their nature, these judgments are subject to an inherent degree of uncertainty. On an on-going basis, we evaluate these estimates, including those related to intangible assets, expenses, and income taxes. We base our estimates on historical experience and other facts and circumstances that are believed to be reasonable, and the results form the basis for making judgments about the carrying values of assets and liabilities. The actual results may differ from these estimates.

We commenced commercial sales and emerged from the development stage in 2012.  We recognize revenue when a contractual arrangement exists, product is shipped, payment from the customer is reasonably assured, and the price is fixed or determinable.  We record customer deposits that have not yet been earned as unearned revenue. Revenue is recognized only when title and risk of loss passes to customers.

14

Any inventory consists of our AsepticSure® product and is valued on a specific identification basis.  We purchase our inventory as a finished product from unrelated manufacturing companies. We write off 100% of the cost of inventory that we specifically identify and consider obsolete or excessive to fulfill future sales estimates. We did not have any inventory as of September 30, 2013.

We account for equity securities issued for services rendered at the fair value of the securities on the date of grant.

Item 3.  Quantitative and Qualitative Disclosures About Market Risk

None.

Item 4.  Controls and Procedures

Evaluation of Disclosure Controls and Procedures

As of September 30, 2013, we updated our evaluation of the effectiveness of the design and operation of our disclosure controls and procedures for purposes of filing reports under the Securities Exchange Act of 1934 (the Exchange Act). This evaluation was done under the supervision and with the participation of management, including our chief executive officer and our chief financial officer. Our chief executive officer and our chief financial officer concluded that as of September 30, 2013, our disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act) are effective to provide reasonable assurance that information that we are required to disclose in the reports that we file or submit to the SEC is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Our disclosure controls and procedures are designed to provide reasonable assurance that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Controls

We maintain a system of internal control over financial reporting that is designed to provide reasonable assurance that our books and records accurately reflect our transactions and that our established policies and procedures are followed. There were no changes to our internal control over financial reporting during our last quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

15

PART II — OTHER INFORMATION

Item 1.  Legal Proceedings

There were no material developments during the quarter ended September 30, 2013 relative to the legal matters previously disclosed by the Company.

Item 2.  Unregistered Sales of Equity Securities and Use of Proceeds

During the quarter ended September 30, 2013, we sold an aggregate of 5,000,000 restricted shares of common stock to eight accredited investors for cash proceeds totaling $300,000, with a price of $0.06 per share. The purchasers of the shares were primarily current stockholders of, but not otherwise affiliated with, the Company. There were no underwriters or public solicitation involved in the offer or sale of these securities. The proceeds are being used for general operating expenses and the continuing development of the AsepticSure® hospital disinfection system. The offer and sale of these securities was made without registration under the Securities Act in reliance upon exemptions from registration, including, without limitation, the exemption provided under Section 4(a)(2) of the Securities Act for private and limited offers and sales of securities made solely to accredited investors.

Item 5.  Other Information

None.

Item 6.  Exhibits

Exhibit 31.1	Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
Exhibit 31.2	Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
Exhibit 32.1	Certification of Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
Exhibit 32.2	Certification of Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS	XBRL Instance Document
101.SCH	XBRL Taxonomy Extension Schema
101.CAL	XBRL Taxonomy Extension Calculation Linkbase
101.DEF	XBRL Taxonomy Extension Definition Linkbase
101.LAB	XBRL Taxonomy Extension Label Linkbase
101.PRE	XBRL Taxonomy Extension Presentation Linkbase

16

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

MEDIZONE INTERNATIONAL, INC.

(Registrant)

/s/ Edwin G. Marshall                                

Edwin G. Marshall, Chairman and Chief Executive

Officer (Principal Executive Officer)

/s/ Thomas (Tommy) E. Auger                 

Thomas (Tommy) E. Auger, Chief Financial Officer

(Principal Financial and Accounting Officer)

October 31, 2013

17

EX-31.1

Exhibit 31.1

CERTIFICATION PURSUANT TO RULE 13a-14

UNDER THE SECURITIES EXCHANGE ACT OF 1934

I, Edwin G. Marshall, certify that:

(1)           I have reviewed this quarterly report on Form 10-Q of Medizone International, Inc. for the quarter ended September 30, 2013;

(2)           Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

(3)           Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(4)           The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:

(a)           Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)           Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)           Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;

(d)           Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting;

(5)           The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions);

(a)           All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information;

(b)           Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: October 31, 2013

/s/	Edwin G. Marshall
	Edwin G. Marshall
	Chief Executive Officer (Principal Executive Officer)

EX-31.2

Exhibit 31.2

CERTIFICATION PURSUANT TO RULE 13a-14

UNDER THE SECURITIES EXCHANGE ACT OF 1934

I, Tommy E. Auger, certify that:

(1)           I have reviewed this quarterly report on Form 10-Q of Medizone International, Inc. for the quarter ended September 30, 2013;

(2)           Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

(3)           Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(4)           The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:

(a)           Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)           Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)           Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;

(d)           Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting;

(5)           The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions);

(a)           All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information;

(b)           Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: October 31, 2013

/s/	Tommy E. Auger
	Tommy E. Auger
	Chief Financial Officer (Principal Financial and Accounting Officer)

EX-32.1

Exhibit 32.1

Certification Pursuant to Section 1350 of Chapter 63

of Title 18 of the United States Code

I, Edwin G. Marshall, the Chief Executive Officer of Medizone International, Inc. (“Medizone”), certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:

(i)           the accompanying Form 10-Q of Medizone for the quarter ended September 30, 2013 (the “Form 10-Q”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(ii)           the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of Medizone.

/s/	Edwin G. Marshall
	Edwin G. Marshall
	Chief Executive Officer (Principal Executive Officer)
	October 31, 2013

EX-32.2

Exhibit 32.2

Certification Pursuant to Section 1350 of Chapter 63

of Title 18 of the United States Code

I, Tommy E. Auger, the Chief Financial Officer of Medizone International, Inc. (“Medizone”), certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:

(i)           the accompanying Form 10-Q of Medizone for the quarter ended September 30, 2013 (the “Form 10-Q”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(ii)           the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of Medizone.

/s/	Tommy E. Auger
	Tommy E. Auger
	Chief Financial Office
	(Principal Financial and Accounting Officer)
	October 31, 2013

XML

NOTE 2 CANADIAN FOUNDATION FOR GLOBAL HEALTH (Details)	9 Months Ended
	Sep. 30, 2013
Disclosure Text Block [Abstract]
Variable Interest Entity, Qualitative or Quantitative Information, Purpose of VIE	(1) to establish an independent not-for-profit foundation intended to have a continuing working relationship with the Company for research purposes that is best positioned to attract the finest scientific, medical and academic professionals possible to work on projects deemed to be of social benefit; and (2) to provide a means for the Company to use a tiered pricing structure for services and products in emerging economies and extend the reach of the Company's technology to as many in need as possible.

XML

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Revenues	$ 0	$ 150,000	$ 379,554	$ 150,000
Operating Expenses:
Cost of revenues	0	86,725	239,436	86,725
General and administrative	263,385	932,872	856,664	2,514,018
Research and development	64,761	187,126	184,643	546,054
Depreciation and amortization	11,420	9,561	37,827	26,488
Total Operating Expenses	339,566	1,216,284	1,318,570	3,173,285
Loss from Operations	(339,566)	(1,066,284)	(939,016)	(3,023,285)
Interest Expense	(6,125)	(6,097)	(18,880)	(18,445)
Net Loss	(345,691)	(1,072,381)	(957,896)	(3,041,730)
Other Comprehensive Loss:
Gain (loss) on foreign currency translation	1,282	957	(86)	(1,589)
Total Comprehensive Loss	$ (344,409)	$ (1,071,424)	$ (957,982)	$ (3,043,319)
Basic and Diluted Net Loss per Common Share (in Dollars per share)	$ 0.00	$ 0.00	$ 0.00	$ (0.01)
Weighted Average Number of Common Shares Outstanding (in Shares)	312,649,052	282,697,797	304,549,347	280,103,399

XML

NOTE 5 COMMITMENTS AND CONTINGENCIES

9 Months Ended

Sep. 30, 2013

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies Disclosure [Text Block]

NOTE 5     COMMITMENTS AND CONTINGENCIES

The Company is subject to certain claims and lawsuits arising in the normal course of business. In the opinion of management, uninsured losses, if any, resulting from the ultimate resolution of these matters will not have a material effect on the Company’s consolidated financial position or results of operations.

Litigation

Rakas vs. Medizone International, Inc. - A former consultant brought this action against the Company claiming the Company had failed to pay consulting fees under a consulting agreement.  In September 2001, the parties agreed to settle the matter for $25,000.  The Company, however, did not have the funds to pay the settlement and the plaintiff moved the court to enter a default judgment in the amount of $143,000 in January 2002.  On May 8, 2002, the court vacated the default judgment and requested that the Company post a bond of $25,000 to cover the settlement previously entered into by the parties.  The Company has been unable to post the required bond amount as of the date of this report.  Therefore, the Company has recorded a liability (included in accounts payable) for the original default judgment of $143,000, plus fees totaling $21,308, as of September 30, 2013 and December 31, 2012.  The Company intends to contest the judgment when it is able to do so in the future.

Other Payables

As of September 30, 2013 and December 31, 2012, the Company has recorded other payables totaling $224,852 for past due amounts owing for which the Company has not received invoices or demands for over 10 years.  Although management of the Company does not believe that the amounts will be paid, the amounts are being recorded as other payables until such time as the Company is certain that no liability exists and until the statute of limitations has expired.

Operating Leases

The Company operates a certified laboratory located at Innovation Park, Queen’s University in Kingston, Ontario, Canada, which provides a primary research and development platform.  The lease term expired on June 30, 2012, and is now month-to-month with a monthly lease payment of $1,375 Canadian dollars (“CD”) plus the applicable goods and services tax (“GST”). A lease for a second laboratory space for full scale room testing and a storage space also expired on June 30, 2012, and is now month-to-month with a monthly lease payment of $1,375 CD and $475 CD, respectively, plus the applicable GST.  

The Company entered into a corporate office lease effective from January 1, 2012 through December 31, 2012 with monthly payments of $2,100.  The lease term was extended for another year, through December 31, 2013, with monthly lease payments increasing from $2,100 to $2,200.  

XML

NOTE 6 COMMON STOCK OPTIONS (Details) - Schedule of Share-Based Compensation, Stock Options, Activity (USD $)	9 Months Ended
	Sep. 30, 2013
Shares [Member]
NOTE 6 COMMON STOCK OPTIONS (Details) - Schedule of Share-Based Compensation, Stock Options, Activity [Line Items]
Outstanding, beginning of the period	17,300,000
Granted	350,000
Expired/Canceled	(2,500,000)
Exercised	0
Outstanding, end of the period	15,150,000
Exercisable	14,000,000
Weighted Average Exercise Price [Member]
NOTE 6 COMMON STOCK OPTIONS (Details) - Schedule of Share-Based Compensation, Stock Options, Activity [Line Items]
Outstanding, beginning of the period (in Dollars per share)	$ 0.17
Granted (in Dollars per share)	$ 0.10
Expired/Canceled (in Dollars per share)	$ 0.05
Exercised (in Dollars per share)	$ 0
Outstanding, end of the period (in Dollars per share)	$ 0.19
Exercisable (in Dollars per share)	$ 0.19

XML

NOTE 3 BASIC AND DILUTED NET LOSS PER COMMON SHARE (Details) (Equity Option [Member])	9 Months Ended
	Sep. 30, 2013
Equity Option [Member]
NOTE 3 BASIC AND DILUTED NET LOSS PER COMMON SHARE (Details) [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,515,000

XML

NOTE 9 SUBSEQUENT EVENTS (Details) (USD $)	9 Months Ended		1 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Oct. 31, 2013 Subsequent Event [Member]
NOTE 9 SUBSEQUENT EVENTS (Details) [Line Items]
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in Shares)			1,950,000
Number of Investors			5
Proceeds from Issuance or Sale of Equity (in Dollars)	$ 1,160,250	$ 1,284,935	$ 97,500
Shares Issued, Price Per Share (in Dollars per share)			$ 0.05

XML

NOTE 8 ACCOUNTS PAYABLE - RELATED PARTIES (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Related Party Transactions [Abstract]
Accounts Payable, Related Parties, Current	$ 234,572	$ 234,572	[1]

[1] The condensed consolidated balance sheet as of December 31, 2012 has been prepared using information from the audited balance sheet as of that date.

XML

NOTE 7 STOCK TRANSACTIONS AND SIGNIFICANT CONTRACTS (Details) (USD $)	9 Months Ended		12 Months Ended		9 Months Ended	3 Months Ended		9 Months Ended						12 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2010 Stock Purchase Agreement [Member]	Dec. 31, 2010 Stock Purchase Agreement [Member] Maximum [Member]	Sep. 30, 2013 Wood Wyant Canada [Member]	Sep. 30, 2013 ADA Innovations [Member]	Sep. 30, 2012 ADA Innovations [Member]	Sep. 30, 2013 ADA Innovations [Member]	Sep. 30, 2012 ADA Innovations [Member]	Sep. 30, 2013 Restricted Stock Issued During August and September 2013 [Member]	Sep. 30, 2013 Restricted Stock Issued During May and June 2013 [Member]	Sep. 30, 2013 Restricted Stock Issued During April and May 2013 [Member]	Sep. 30, 2013 Restricted Stock Issued During January, February and March 2013 [Member]	Dec. 31, 2012 Restricted Stock Issued During January and February 2012 [Member]	Dec. 31, 2012 Restricted Stock Issued During July, August and September 2012 [Member]	Dec. 31, 2012 Minimum [Member] Restricted Stock Issued During July, August and September 2012 [Member]	Sep. 30, 2013 Minimum [Member]	Dec. 31, 2012 Minimum [Member]	Dec. 31, 2012 Maximum [Member] Restricted Stock Issued During July, August and September 2012 [Member]	Sep. 30, 2013 Maximum [Member]	Dec. 31, 2012 Maximum [Member]
NOTE 7 STOCK TRANSACTIONS AND SIGNIFICANT CONTRACTS (Details) [Line Items]
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in Shares)										5,000,000	5,863,636	3,794,444	12,233,332	6,653,000	5,233,333
Number of Investors										8	11	6	12	30	11
Proceeds from Issuance or Sale of Equity (in Dollars)	$ 1,160,250	$ 1,284,935								$ 300,000	$ 322,500	$ 170,750	$ 367,000	$ 665,300	$ 296,500
Shares Issued, Price Per Share (in Dollars per share)										$ 0.06	$ 0.055	$ 0.045	$ 0.03	$ 0.10		$ 0.05	$ 0.03	$ 0.05	$ 0.09	$ 0.06	$ 0.165
Stock Repurchase Program, Period in Force			2 years
Common Stock, Share Subscribed but Unissued, Subscriptions Receivable			10,000,000
Equity Method Investment, Ownership Percentage				4.90%
Stock purchase agreement, price description			75% of the lowest closing bid price during the five consecutive trading-day period (the "Draw Down Pricing Period") preceding the date a draw down notice (the "Draw Down Notice") was delivered by the Company to Mammoth (the "Draw Down Date") in a manner provided by the Stock Purchase Agreement
Supply Commitment, Description					The Company delivered an initial order for five systems to Wood Wyant for proceeds totaling $375,000.The Company has six more systems in production.
Sales Revenue, Goods, Gross					375,000
Research and Development Expense, Software (Excluding Acquired in Process Cost)						$ 0	$ 49,000	$ 0	$ 157,000

XML

NOTE 1 BASIS OF PRESENTATION

9 Months Ended

Sep. 30, 2013

Disclosure Text Block [Abstract]

Business Description and Basis of Presentation [Text Block]

NOTE 1     BASIS OF PRESENTATION

The financial information included herein is unaudited and has been prepared consistent with United States generally accepted accounting principles (“US GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, these condensed consolidated financial statements do not include all information and notes required by US GAAP for complete financial statements. These notes should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2012. In the opinion of management, these financial statements contain all adjustments (consisting solely of normal recurring adjustments) which are, in the opinion of management, necessary to provide a fair presentation for the interim periods. The results of operations for the three and nine months ended September 30, 2013 are not necessarily indicative of the results to be expected for the full year.

XML

NOTE 3 BASIC AND DILUTED NET LOSS PER COMMON SHARE

9 Months Ended

Sep. 30, 2013

Earnings Per Share [Abstract]

Earnings Per Share [Text Block]

NOTE 3     BASIC AND DILUTED NET LOSS PER COMMON SHARE

The computations of basic and diluted net loss per common share are based on the weighted average number of common shares outstanding during the periods as follows:

	For the Three Months Ended September 30,
	2013			2012
Numerator: Net loss	$	(345,691	)	$	(1,072,381	)
Denominator: Weighted average number of common shares outstanding		312,649,052			282,697,797
Basic and diluted net loss per common share	$	(0.00	)	$	(0.00	)

	For the Nine Months Ended September 30,
	2013			2012
Numerator: Net loss	$	(957,896	)	$	(3,041,730	)
Denominator: Weighted average number of common shares outstanding		304,549,347			280,103,399
Basic and diluted net loss per common share	$	(0.00	)	$	(0.01	)

Common stock equivalents, consisting of options to purchase a total of 15,150,00 shares of common stock, have not been included in the calculation as their effect is antidilutive for the periods presented.

XML

NOTE 6 COMMON STOCK OPTIONS

9 Months Ended

Sep. 30, 2013

Disclosure Text Block Supplement [Abstract]

Shareholders' Equity and Share-based Payments [Text Block]

NOTE 6     COMMON STOCK OPTIONS

On August 26, 2009, the Company granted options for the purchase of 1,500,000 shares of common stock to an outside consultant for services rendered, with an exercise price of $0.10 per share, exercisable for up to five years, but including vesting provisions as follows: (i) options for 500,000 shares vested immediately on the date of grant, (ii) options for 500,000 shares vested in September 2012, the date certified by the Company as the date its hospital disinfection program completed its beta-testing, and (iii) the remaining options for 500,000 shares will vest on the date certified by the Company as the date that its disinfection process has been commercialized and a minimum of 50 units or devices have been sold to third parties.  During the three months ended September 30, 2012, options for 500,000 shares valued at $48,699 vested, and were recorded as part of general and administrative expenses. As of September 30, 2013, options for 500,000 shares had not yet vested.

In July 2010, the Company granted options for the purchase of 3,500,000 shares of common stock (of which 250,000 were cancelled in 2011) to certain board members and employees of the Company for services rendered.  These options are exercisable for five years from the date of grant at $0.20 per share, and the remaining options vested when the Company achieved commercial sales during the third quarter of 2012, resulting in $659,822 being recorded as part of general and administrative expense. 

In September 2010, the Company granted options for the purchase of 250,000 shares of common stock to a consultant in connection with extending his consulting agreement with the Company through September 2011.  These options are exercisable at $0.275 per share for five years from the date of grant and vested when the Company achieved commercial sales during the third quarter of 2012, resulting in $65,067 being recorded as part of general and administrative expense.  

In February 2012, the Board of Directors approved the 2012 Equity Incentive Award Plan and authorized up to 10,000,000 shares of common stock to be available for awards under the Plan.  On February 21, 2012, each of four directors of the Company was awarded stock options for the purchase of 1,000,000 shares of common stock, exercisable at a price of $0.23 per share, which was the fair value of the common stock based on the price of the Company’s common stock reported on the OTC Bulletin Board on the date of grant.  In addition, certain officers, consultants and employees of the Company were awarded options for the purchase of an aggregate 1,050,000 shares of common stock at an exercise price of $0.23 per share.  The value of these options granted, totaling $1,057,600, was recognized as expense during the nine months ended September 30, 2012 as each of the options granted was fully vested on the date of grant.

In May 2012, the Company granted options for the purchase of 1,000,000 shares of common stock to an individual for services.  Options for 550,000 shares have vested and the remaining options will vest on the date certified by the Company as the date that the other milestones are achieved.  The options have an exercise price of $0.15 per share, and are exercisable for up to five years.  The value of these options granted was $153,997 in connection with which the Company recognized $69,300 during the nine months ended September 30, 2013.  As of September 30, 2013, options for the purchase of 550,000 shares have vested.

In May 2012, the Company granted options for the purchase of 1,000,000 shares of common stock to an individual for medical consulting support services already performed and to be performed in the future.  The options have an exercise price of $0.17 per share, and are exercisable for up to five years.  The value of the options vested upon grant was $149,460, of which the Company recognized $49,322 and $100,138 during the nine months ended September 30, 2013 and 2012, respectively.  As of September 30, 2013, all of the milestones were achieved and all of the shares vested.

In August 2012, the Company granted options for the purchase of 2,500,000 shares of common stock to three individuals in connection with the purchase of restricted stock, exercisable at a price of $0.05 per share.  No expense was recorded for these options as the value associated with these options was recorded as part of the stock transactions.  These options held a six-month term and have expired without being exercised. 

In August 2013, the Company granted options for the purchase of 250,000 shares of common stock to a consultant.  These options are exercisable at $0.10 per share for five years from the date of grant with 50,000 shares vesting immediately and the other 200,000 upon the achievement of certain milestones.  The value of these options granted was $22,075 of which the Company recognized $4,415 which was recorded as part of general and administrative expense during the three months ended September 30, 2013.  

In August 2013, the Company granted options for the purchase of 100,000 shares of common stock to an employee for services already performed.  The options have an exercise price of $0.10 per share, and are exercisable for up to five years.  The value of the options vested upon grant was $8,830 which the Company recorded as part of general and administrative expense during the three months ended September 30, 2013.

The Company estimated the fair value of the stock options described in the above paragraphs at the date of the grant, based on the following weighted average assumptions:

Risk-free interest rate	.75	%	to	1.66	%
Expected life				5 years
Expected volatility	138.3	%	to	148.9	%
Dividend yield				0.00	%

A summary of the status of the Company’s outstanding options as of September 30, 2013, and for the nine months then ended, is presented below:

	Shares			Weighted Average Exercise Price
Outstanding, beginning of the period		17,300,000		$	0.17
Granted		350,000			0.10
Expired/Canceled		(2,500,000	)		0.05
Exercised		-			-
Outstanding, end of the period		15,150,000			0.19
Exercisable		14,000,000		$	0.19

The Company estimates the fair value of each stock award by using the Black-Scholes option-pricing model, which model requires the use of exercise behavior data and the use of a number of assumptions including volatility of the Company’s stock price, the weighted average risk-free interest rate, and the weighted average expected life of the options. Because the Company does not pay dividends, the dividend rate variable in the Black-Scholes option-pricing model is zero. Expense of $131,866 and $1,931,325 related to stock options was recorded for the nine months ended September 30, 2013 and 2012, respectively.  As of September 30, 2013, the Company had various unvested outstanding options with related unrecognized expense of $135,657.  The Company will recognize this expense as these options vest over their remaining lives, which range from 11 to 59 months.

XML

NOTE 4 GOING CONCERN

9 Months Ended

Sep. 30, 2013

Going Concern Disclosure [Abstract]

Going Concern Disclosure [Text Block]

NOTE 4     GOING CONCERN

The Company’s consolidated financial statements are prepared using US GAAP applicable to a going concern which contemplates the realization of assets and settlement of liabilities in the normal course of business.  The Company has incurred significant losses from its inception through September 30, 2013, which have resulted in an accumulated deficit of $31,042,888 as of September 30, 2013.  The Company does not have funds sufficient to cover its operating costs for the next 12 months, has a working capital deficit of $2,980,355, and has relied on debt and equity financing to sustain its operations.  Accordingly, there is substantial doubt about its ability to continue as a going concern.

Continuation of the Company as a going concern is dependent upon future revenues, obtaining additional capital and ultimately, upon the Company’s attaining profitable operations.  The Company will require substantial, additional funds to complete the development of its products, perform hospital beta testing and fund additional losses, until future revenues are sufficient to cover the Company’s operating expenses. If the Company is unsuccessful in obtaining additional funding, it may be forced to substantially reduce or cease operations.

The Company believes that it will need approximately $2,000,000 over the next 12 months for continuing research expenses, marketing, and related activities, as well as for general corporate purposes, including expanded manufacturing and sales.  

During 2012, the Company raised a total of $1,420,793 through the sale of 16,729,278 shares of common stock at prices ranging from $0.05 to $0.165 per share, which funds have been used pay current obligations and to pay for the initial costs of development for its hospital disinfection system.  During the nine months ended September 30, 2013, the Company raised a total of $1,160,250 through the sale of 26,891,412 shares of common stock at prices ranging from $0.03 to $0.06 per share.  The Company believes it will be able to raise additional funds from some of the same investors who have purchased shares from 2009 to 2013, although there is no guarantee that these investors will purchase additional shares.  Certain of these investors have orally committed to continue to fund the Company’s projects on a monthly basis.

Continuing as a going concern is dependent on the Company’s ability to successfully accomplish the plan described in the preceding paragraphs and eventually attain profitable operations.  The consolidated financial statements do not include any adjustments relating to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities that might result from the outcome of these uncertainties.

XML

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Preferred stock, shares authorized (in Shares)	50,000,000	50,000,000	[1]
Preferred stock, par value (in Dollars per share)	$ 0.00001	$ 0.00001	[1]
Preferred stock, shares issued (in Shares)	0	0	[1]
Preferred stock, shares outstanding (in Shares)	0	0	[1]
Common stock, shares authorized (in Shares)	395,000,000	395,000,000	[1]
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001	[1]
Common stock, shares issued (in Shares)	315,662,639	288,771,227	[1]
Common stock, shares outstanding (in Shares)	315,662,639	288,771,227	[1]

[1] The condensed consolidated balance sheet as of December 31, 2012 has been prepared using information from the audited balance sheet as of that date.

XML

NOTE 9 SUBSEQUENT EVENTS

9 Months Ended

Sep. 30, 2013

Subsequent Events [Abstract]

Subsequent Events [Text Block]

NOTE 9     SUBSEQUENT EVENTS

The Company has evaluated events subsequent to September 30, 2013 for potential accounting or disclosure in the accompanying financial statements, noting the following.  During October 2013, the Company sold 1,950,000 restricted shares of common stock to 5 accredited investors for cash proceeds totaling $97,500, or $0.05 per share.

XML

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	9 Months Ended
	Sep. 30, 2013		Sep. 30, 2012
Cash Flows from Operating Activities:
Net loss	$ (957,896)		$ (3,041,730)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	37,576		26,416
Value of stock options granted	131,866		1,931,325
Changes in operating assets and liabilities:
Prepaid expenses	(144,343)		28,724
Inventory	45,548		(91,547)
Customer deposits	(4,554)		10,000
Accounts payable (includes related parties)	(15,280)		59,931
Accrued expenses (includes related parties)	(29,483)		26,611
Net Cash Used in Operating Activities	(936,566)		(1,050,270)
Cash Flows from Investing Activities:
Purchase of trademark and patents	(36,551)		(89,118)
Purchase of property and equipment	(7,540)		(3,148)
Net Cash Used in Investing Activities	(44,091)		(92,266)
Cash Flows from Financing Activities:
Principal payments on notes payable	(51,189)		(26,449)
Issuance of common stock for cash	1,160,250		1,284,935
Net Cash Provided by Financing Activities	1,109,061		1,258,486
Effect of Foreign Currency Exchange Rates	(86)		(1,589)
Net increase in cash	128,318		114,361
Cash as of beginning of the period	12,456	[1]	129,759
Cash as of end of the period	140,774		244,120
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash Paid for Interest	697		702
NON-CASH FINANCING ACTIVITIES:
Financing of insurance policies	$ 62,987		$ 54,678

[1] The condensed consolidated balance sheet as of December 31, 2012 has been prepared using information from the audited balance sheet as of that date.

XML

Condensed Consolidated Balance Sheets (Unaudited) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Current Assets:
Cash	$ 140,774	$ 12,456	[1]
Inventory	0	45,548	[1]
Prepaid expenses	325,674	118,344	[1]
Total Current Assets	466,448	176,348	[1]
Property and Equipment, net	8,162	5,964	[1]
Other Assets:
Trademark and patents, net	212,808	208,490	[1]
Lease deposit	4,272	4,272	[1]
Total Other Assets	217,080	212,762	[1]
Total Assets	691,690	395,074	[1]
Current Liabilities:
Accounts payable	438,606	453,885	[1]
Accounts payable – related parties	234,572	234,572	[1]
Accrued expenses	504,632	487,690	[1]
Accrued expenses – related parties	1,928,659	1,975,084	[1]
Customer deposits	30,000	34,554	[1]
Notes payable	310,334	298,536	[1]
Total Current Liabilities	3,446,803	3,484,321	[1]
Other Payables	224,852	224,852	[1]
Total Liabilities	3,671,655	3,709,173	[1]
Commitments and Contingencies (Notes 4 and 5)			[1]
Stockholders’ Deficit:
Preferred stock, $0.00001 par value; 50,000,000 shares authorized, no shares issued or outstanding	0	0	[1]
Common stock, $0.001 par value, 395,000,000 shares authorized, 315,662,639 and 288,771,227 shares issued and outstanding, respectively	315,663	288,771	[1]
Additional paid-in capital	27,771,790	26,506,566	[1]
Accumulated other comprehensive loss	(24,530)	(24,444)	[1]
Accumulated deficit	(31,042,888)	(30,084,992)	[1]
Total Stockholders' Deficit	(2,979,965)	(3,314,099)	[1]
Total Liabilities and Stockholders’ Deficit	$ 691,690	$ 395,074	[1]

[1] The condensed consolidated balance sheet as of December 31, 2012 has been prepared using information from the audited balance sheet as of that date.

XML

NOTE 6 COMMON STOCK OPTIONS (Details) - Schedule of Fair Value Assumptions of Stock Options	9 Months Ended
	Sep. 30, 2013
Schedule of Fair Value Assumptions of Stock Options [Abstract]
Risk-free interest rate	1.66%
Risk-free interest rate	0.75%
Expected life	5 years
Expected volatility	138.30%
Expected volatility	148.90%
Dividend yield	0.00%

XML

NOTE 8 ACCOUNTS PAYABLE - RELATED PARTIES

9 Months Ended

Sep. 30, 2013

Related Party Transactions [Abstract]

Related Party Transactions Disclosure [Text Block]

NOTE 8     ACCOUNTS PAYABLE – RELATED PARTIES

As of September 30, 2013 and December 31, 2012, the Company had payables of $234,572, owed to certain consultants for services rendered in prior years. These consultants are stockholders of the Company and therefore have been classified as related parties.

XML

NOTE 6 COMMON STOCK OPTIONS (Tables)

9 Months Ended

Sep. 30, 2013

Disclosure Text Block Supplement [Abstract]

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

The Company estimated the fair value of the stock options described in the above paragraphs at the date of the grant, based on the following weighted average assumptions:

Risk-free interest rate	.75	%	to	1.66	%
Expected life				5 years
Expected volatility	138.3	%	to	148.9	%
Dividend yield				0.00	%

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

A summary of the status of the Company’s outstanding options as of September 30, 2013, and for the nine months then ended, is presented below:

	Shares			Weighted Average Exercise Price
Outstanding, beginning of the period		17,300,000		$	0.17
Granted		350,000			0.10
Expired/Canceled		(2,500,000	)		0.05
Exercised		-			-
Outstanding, end of the period		15,150,000			0.19
Exercisable		14,000,000		$	0.19

XML

NOTE 7 STOCK TRANSACTIONS AND SIGNIFICANT CONTRACTS

9 Months Ended

Sep. 30, 2013

Stockholders' Equity Note [Abstract]

Stockholders' Equity Note Disclosure [Text Block]

NOTE 7     STOCK TRANSACTIONS AND SIGNIFICANT CONTRACTS

During August and September 2013, the Company sold 5,000,000 restricted shares of common stock to eight accredited investors for cash proceeds totaling $300,000, or $0.06 per share.

During May and June 2013, the Company sold 5,863,636 restricted shares of common stock to 11 accredited investors for cash proceeds totaling $322,500, or $0.055 per share.

During April and May 2013, the Company sold 3,794,444 restricted shares of common stock to six accredited investors for cash proceeds totaling $170,750, or $0.045 per share.

During January, February, and March 2013, the Company sold an aggregate of 12,233,332 restricted shares of common stock to 12 accredited investors for cash proceeds totaling $367,000, or $0.03 per share.

During January and February 2012, the Company sold an aggregate of 6,653,000 restricted shares of common stock to 30 accredited investors for cash proceeds of $665,300, or $0.10 per share.

During July, August and September 2012, the Company sold an aggregate of 5,233,333 restricted shares of common stock to 11 accredited investors for cash proceeds of $296,500 at prices ranging from $0.05 to $0.09 per share.

Stock Purchase Agreement

In November 2010, the Company entered into a two-year Stock Purchase Agreement with Mammoth providing for the Equity Line. The Stock Purchase Agreement provided that, upon the terms and subject to the conditions in the Stock Purchase Agreement, Mammoth committed to purchase up to $10,000,000 of shares of common stock over the term of the Stock Purchase Agreement under certain specified conditions and limitations. Mammoth was barred from purchasing any shares of the Company’s common stock which, when aggregated with all other shares of common stock then beneficially owned by Mammoth, would result in the beneficial ownership by Mammoth of more than 4.9% of the then outstanding shares of the Company’s common stock. These maximum share and beneficial ownership limitations could not be waived by the parties.

Under the terms of the Stock Purchase Agreement, the Company had the opportunity for a 24-month period, commencing on the date on which the Securities and Exchange Commission (“SEC”) first declared effective the registration statement filed in connection with the resale of shares issued under the Equity Line, to require Mammoth to purchase up to $10,000,000 in shares of common stock. For each share of common stock purchased under the Stock Purchase Agreement, Mammoth would pay a purchase price equal to 75% of the lowest closing bid price during the five consecutive trading-day period (the “Draw Down Pricing Period”) preceding the date a draw down notice (the “Draw Down Notice”) was delivered by the Company to Mammoth (the “Draw Down Date”) in a manner provided by the Stock Purchase Agreement.  The SEC declared the registration statement effective on January 25, 2011.  The Stock Purchase Agreement and Equity Line terminated on January 25, 2013.

Wood Wyant Canada

In April 2013, the Company and Wood Wyant Canada (“Wood Wyant”), a subsidiary of Sanimarc Group, announced that Wood Wyant had become a National Hospital Distributor of AsepticSure® in Canada.  Wood Wyant serves Canada from 16 locations across all 10 provinces, providing both sales and service to the hospital market.  The Company delivered an initial order for five systems to Wood Wyant for proceeds totaling $375,000.  The Company has six more systems in production.

ADA Innovations

In December 2010, the Company reached a Services Agreement with ADA Innovations (“ADA”) for final development and production manufacturing of portable versions (the “Projects”) of the Company’s AsepticSure® disinfection systems.  A contract containing the terms of the agreement and detailed development plan was executed by the parties in January 2011 and amended in January 2012.  Any and all notes, reports, information, inventions, sketches, plans, concepts, data or other works created by ADA on its behalf under the Services Agreement will be the sole and exclusive property of the Company.

The term of the Services Agreement continues until the completion of the development and design projects contemplated by the Services Agreement, unless terminated earlier by either party in accordance with specific notices as outlined in the Services Agreement.  Deliverables include: (1) the pre-production prototype designed and manufactured to the Company’s specifications, (2) design and device content compliant with all North America, Europe and United Kingdom regulatory and licensing agency regulations, (3) a soft launch program managed by ADA and the Company, intended to be followed by increased production, and (4) additional outsourced macro-manufacturing capacity as required, supervised by the parties.  The Company paid ADA as services were provided and were completed by December 31, 2012.  During the three and nine months ended September 30, 2012, the Company incurred expenses totaling approximately $49,000 and $157,000, respectively, for services provided under the Services Agreement, which expenses have been included in research and development expense.  No expenses under this contract were incurred during the three and nine months ended September 30, 2013.  ADA’s role as developer of the production AsepticSure® system is now complete.  ADA remains available to the Company on a limited basis as a consultant.

XML

NOTE 2 CANADIAN FOUNDATION FOR GLOBAL HEALTH

9 Months Ended

Sep. 30, 2013

Disclosure Text Block [Abstract]

Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]

NOTE 2     CANADIAN FOUNDATION FOR GLOBAL HEALTH

In late 2008, the Company assisted in the formation of the Canadian Foundation for Global Health (“CFGH”), a not-for-profit foundation based in Ottawa, Canada. The Company helped establish CFGH for two primary purposes: (1) to establish an independent not-for-profit foundation intended to have a continuing working relationship with the Company for research purposes that is best positioned to attract the finest scientific, medical and academic professionals possible to work on projects deemed to be of social benefit; and (2) to provide a means for the Company to use a tiered pricing structure for services and products in emerging economies and extend the reach of the Company’s technology to as many in need as possible.

US GAAP requires a variable interest entity (“VIE”) to be consolidated by a company if that company absorbs a majority of the VIE’s expected losses and/or receives a majority of the entity’s expected residual returns as a result of holding variable interests, which are the ownership, contractual, or other financial interests in the entity. In addition, a legal entity may be considered to be a VIE, if it does not have sufficient equity at risk to finance its own activities without relying on financial support from other parties. If the legal entity is a VIE, then the reporting entity determined to be the primary beneficiary of the VIE must consolidate the VIE’s financial statements with its own. The Company determined that CFGH meets the requirements of a VIE effective upon the first advance to CFGH on February 12, 2009. Accordingly, the financial position and operations of CFGH have been consolidated with the Company for all periods presented.

XML

NOTE 3 BASIC AND DILUTED NET LOSS PER COMMON SHARE (Details) - Schedule of Earnings Per Share (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Schedule of Earnings Per Share [Abstract]
Numerator: Net loss (in Dollars)	$ (345,691)	$ (1,072,381)	$ (957,896)	$ (3,041,730)
Denominator: Weighted average number of common shares outstanding	312,649,052	282,697,797	304,549,347	280,103,399
Basic and diluted net loss per common share (in Dollars per share)	$ 0.00	$ 0.00	$ 0.00	$ (0.01)

XML

NOTE 3 BASIC AND DILUTED NET LOSS PER COMMON SHARE (Tables)

9 Months Ended

Sep. 30, 2013

Earnings Per Share [Abstract]

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

The computations of basic and diluted net loss per common share are based on the weighted average number of common shares outstanding during the periods as follows:

	For the Three Months Ended September 30,
	2013			2012
Numerator: Net loss	$	(345,691	)	$	(1,072,381	)
Denominator: Weighted average number of common shares outstanding		312,649,052			282,697,797
Basic and diluted net loss per common share	$	(0.00	)	$	(0.00	)

	For the Nine Months Ended September 30,
	2013			2012
Numerator: Net loss	$	(957,896	)	$	(3,041,730	)
Denominator: Weighted average number of common shares outstanding		304,549,347			280,103,399
Basic and diluted net loss per common share	$	(0.00	)	$	(0.01	)

XML

NOTE 6 COMMON STOCK OPTIONS (Details) (USD $)	9 Months Ended		12 Months Ended	9 Months Ended	12 Months Ended	9 Months Ended	12 Months Ended	9 Months Ended		12 Months Ended		9 Months Ended	12 Months Ended		9 Months Ended	12 Months Ended		9 Months Ended	12 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012 2012 Equity Incentive Award Plan [Member] Options Granted to Directors, February 2012 [Member]	Sep. 30, 2012 2012 Equity Incentive Award Plan [Member] Options Granted to Officers, Consultants and Employees, February 2012 [Member]	Dec. 31, 2012 2012 Equity Incentive Award Plan [Member] Options Granted to Officers, Consultants and Employees, February 2012 [Member]	Sep. 30, 2013 2012 Equity Incentive Award Plan [Member] Options Issued for Distribution Related Services, May 2012 [Member]	Dec. 31, 2012 2012 Equity Incentive Award Plan [Member] Options Issued for Distribution Related Services, May 2012 [Member]	Sep. 30, 2013 2012 Equity Incentive Award Plan [Member] Options Granted for Medical Consulting Support Services, May 2012 [Member]	Sep. 30, 2012 2012 Equity Incentive Award Plan [Member] Options Granted for Medical Consulting Support Services, May 2012 [Member]	Dec. 31, 2012 2012 Equity Incentive Award Plan [Member] Options Granted for Medical Consulting Support Services, May 2012 [Member]	Dec. 31, 2012 2012 Equity Incentive Award Plan [Member]	Sep. 30, 2012 Stock Options Issued August 26, 2009 [Member]	Dec. 31, 2009 Stock Options Issued August 26, 2009 [Member]	Sep. 30, 2013 Stock Options Issued August 26, 2009 [Member]	Sep. 30, 2012 Stock Options Issued July 2010 [Member]	Dec. 31, 2011 Stock Options Issued July 2010 [Member]	Dec. 31, 2010 Stock Options Issued July 2010 [Member]	Sep. 30, 2012 Options Granted September 2010 [Member]	Dec. 31, 2010 Options Granted September 2010 [Member]	Dec. 31, 2012 Options Granted with Purchase of Restricted Stock, August 2012 [Member]	Sep. 30, 2013 Options Granted to a Consultant in August 2013 [Member]	Sep. 30, 2013 Options Granted to Employee for Services in August 2013 [Member]	Sep. 30, 2013 Minimum [Member]	Sep. 30, 2013 Maximum [Member]
NOTE 6 COMMON STOCK OPTIONS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			1,000,000		1,050,000		1,000,000			1,000,000			1,500,000				3,500,000		250,000	2,500,000	250,000	100,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights													500,000 shares of common stock to an outside consultant for services rendered, with an exercise price of $0.10 per share, exercisable for up to five years, but including vesting provisions as follows: (i) options for 500,000 shares vested immediately on the date of grant, (ii) options for 500,000 shares vested in September 2012, the date certified by the Company as the date its hospital disinfection program completed its beta-testing, and (iii) the remaining options for 500,000 shares will vest on the date certified by the Company as the date that its disinfection process has been commercialized and a minimum of 50 units or devices have been sold to third parties.
Share-based Compensation by Share-based Payment Award, Options, Exercise Price of Options (in Dollars per share)			$ 0.23		$ 0.23		$ 0.15			$ 0.17			$ 0.10				$ 0.20		$ 0.275	$ 0.05	$ 0.10	$ 0.10
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period							5 years			5 years			5 years				5 years		5 years	6 months	5 years	5 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares	550,000											500,000									50,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value (in Dollars)										$ 149,460		$ 48,699										$ 8,830
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares														500,000							200,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period																250,000
Share-based Compensation (in Dollars)	131,866	1,931,325		1,057,600		69,300		49,322	100,138						659,822			65,067			4,415
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized											10,000,000
Number of directors issued options			4
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number							550,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Fair Value Grants in Period (in Dollars)						153,997															22,075
Number of Investors																				3
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options (in Dollars)	$ 135,657
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term																							11 months	59 months

XML

NOTE 4 GOING CONCERN (Details) (USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2013	Dec. 31, 2012
NOTE 4 GOING CONCERN (Details) [Line Items]
Retained Earnings (Accumulated Deficit) (in Dollars)	$ (31,042,888)	$ (30,084,992)	[1]
Working capital (deficit) (in Dollars)	(2,980,355)
Going Concern Note	The Company believes that it will need approximately $2,000,000 over the next 12 months for continuing research expenses, marketing, and related activities, as well as for general corporate purposes, including expanded manufacturing and sales.
Stock Issued During Period, Value, New Issues (in Dollars)	$ 1,160,250	$ 1,420,793
Stock Issued During Period, Shares, New Issues (in Shares)	26,891,412	16,729,278
Minimum [Member]
NOTE 4 GOING CONCERN (Details) [Line Items]
Shares Issued, Price Per Share (in Dollars per share)	$ 0.03	$ 0.05
Maximum [Member]
NOTE 4 GOING CONCERN (Details) [Line Items]
Shares Issued, Price Per Share (in Dollars per share)	$ 0.06	$ 0.165

[1] The condensed consolidated balance sheet as of December 31, 2012 has been prepared using information from the audited balance sheet as of that date.

XML

Document And Entity Information	9 Months Ended
	Sep. 30, 2013	Oct. 31, 2013
Document and Entity Information [Abstract]
Entity Registrant Name	Medizone International Inc
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		317,612,639
Amendment Flag	false
Entity Central Index Key	0000753772
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Well-known Seasoned Issuer	No
Document Period End Date	Sep. 30, 2013
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	Q3

XML

NOTE 5 COMMITMENTS AND CONTINGENCIES (Details)								9 Months Ended				12 Months Ended	9 Months Ended
	Sep. 30, 2013 USD ($)	Dec. 31, 2012 USD ($)		Sep. 30, 2013 Default Judgement [Member] Rakas Litigation [Member] USD ($)	Dec. 31, 2012 Default Judgement [Member] Rakas Litigation [Member] USD ($)	Sep. 30, 2013 Litigation Fees [Member] Rakas Litigation [Member] USD ($)	Dec. 31, 2012 Litigation Fees [Member] Rakas Litigation [Member] USD ($)	Sep. 30, 2013 Laboratory Storage Space [Member] CAD	Sep. 30, 2013 Full Scale Room Testing [Member] CAD	Sep. 30, 2013 Storage Space [Member] CAD	Sep. 30, 2013 Corporate Offices [Member] USD ($)	Dec. 31, 2012 Corporate Offices [Member] USD ($)	Sep. 30, 2013 Settlement Amount, September 2001 [Member] Rakas Litigation [Member] USD ($)
NOTE 5 COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Litigation Settlement, Amount													$ 25,000
Accounts Payable, Current	438,606	453,885	[1]	143,000	143,000	21,308	21,308
Other Liabilities, Noncurrent	224,852	224,852	[1]
Operating Leases, Rent Expense, Minimum Rentals (in Dollars)								1,375	1,375	475	2,200	2,100
Operating Leases, Rent Expense, Minimum Rentals								1,375	1,375	475	$ 2,200	$ 2,100

[1] The condensed consolidated balance sheet as of December 31, 2012 has been prepared using information from the audited balance sheet as of that date.